Safety and efficacy of colesevelam HCl in the treatment of elderly patients

Drugs and Aging

Volumn 31, Issue 6, 2014, Pages 461-470

  Gavin III, James R ^a   Jones, Michael R ^b,c   Ford, Daniel M ^b   Truitt, Kenneth E ^b  

^a Healing Our Village Inc   (United States)

^b DAIICHI SANKYO INC   (United States)

^c Daiichi Sankyo Pharma Development ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; COLESEVELAM; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA; ALLYLAMINE; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADD ON THERAPY; ADULT; AGED; AGING; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; GROUPS BY AGE; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE STRAIN; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SINUSITIS; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; AGE; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; HYPERLIPIDEMIAS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903698437     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0174-4     Document Type: Article

References (61)

1. Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113(5):647-56. doi:10.1161/CIRCULATIONAHA.105.552737.
2. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet. 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011pdf. Accessed 4 Dec 2013.
3. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci. 2009. doi:10.1093/gerona/gln016.
4. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-67. (Pubitemid 30112269)
6. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008. doi:10.2337/dc08-S061.
7. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.1161/01.cir.0000437738.63853.7a.
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. doi:10.1056/NEJMoa040583.
9. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005. doi:10.1016/S0140-6736(05)67394-1.
10. Cheung BMY, Ong KL, Cherny SS, Sham P-C, Tso AWK, Lam KSL. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009. doi:10.1016/j.amjmed.2008.09.047.
11. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12. (Pubitemid 29254858)
12. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12. (Pubitemid 30609442)
13. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012. doi:10.2337/dc12-0413.
14. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012. doi:10.2337/dc12-1801.
15. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013. doi:10.2337/dc13-S011.
16. El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011. doi:10.1002/mus.22205.
17. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011. doi:10.1056/NEJMsa1103053.
18. Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012. doi:10.1186/1475-2840-11-122.
19. Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger J-B, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab. 2013. doi:10.1111/dom.12031.
20. Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012. doi:10.1111/j.1463-1326.2012. 01583.x.
21. Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009. doi:10.2337/dc09-0114.
22. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007. doi:10.1016/S0140-6736(07)61514-1.
23. Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 2012. doi:10.1007/s00125-012-2668-0.
24. Takeda Pharmaceuticals America, Inc. Pioglitazone prescribing information. 2013. http://www.takeda.us/products/. Accessed Nov 2013.
25. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipidaltering drug. Expert Opin Pharmacother. 2003. doi:10.1517/14656566.4.5.779.
26. Beysen C, Murphy EJ, Deines K, Chan M, Tsang E, Glass A, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012. doi:10.1007/s00125-011-2382-3.
27. Smushkin G, Sathananthan M, Piccinini F, Dalla Man C, Law JH, Cobelli C et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2013. doi:10.2337/db12-0923.
28. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glu-cagon- like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005. doi:10.1016/j.bbrc.2005.01.139.
29. Daiichi Sankyo Inc. WELCHOL (colesevelam hydrochloride) US prescribing information. 2014. http://dsi.com/prescribing-information-portlet/getDocument? product=WC&inline=true. Accessed 02 Feb 2014.
30. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159:1893-900. (Pubitemid 29424709)
31. Insull W Jr, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001. doi:10.4065/76.10.971.
32. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008. doi:10.1001/archinte.168.18. 1975.
33. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008. doi:10.2337/dc08-0283.
34. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008. doi:10.1001/archinte.168.14.1531.
35. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007. doi:10.1016/j.clinthera.2007.01.003.
36. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99:257-73.
37. Study of the Effectiveness of Additional Reductions in Cholesterol Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010. doi:10.1016/S0140- 6736(10)60310-8.
38. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA. 2000;284:1263-70.
39. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010. doi:10.1016/S0140-6736(09)61965-6.
40. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013. doi:10.1111/j.1365-2125.2012.04403.x.
41. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011. doi:10.1001/jama.2011.860.
42. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012. doi:10.1016/S0140-6736(12)61190-8.
43. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006. doi:10.1016/j.amjcard.2005.11.039.
44. Talley NJ, Fleming KC, Evans JM, O'Keefe EA, Weaver AL, Zinsmeister AR, et al. Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol. 1996;91:19-25. (Pubitemid 26026031)
45. Saenz A, Fernandez-Esteban I, Mataix A, Segura MA, Roquéi Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005. doi:10.1002/14651858.CD002966.pub3.
46. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010. doi:10.4158/EP10130.OR.
47. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386-99. (Pubitemid 351664540)
48. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6-14. (Pubitemid 38067945)
49. Bristol-Myers Squibb Company. GLUCOPHAGE XR (metformin hydrochloride) extended-release tablets-US prescribing information. 2009. http:// packageinserts.bms.com/pi/pi-glucophage.pdf. Accessed 02 Feb 2014.
50. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009. doi:10.1016/j.amjopharm.2009.12.002.
51. Rubenfire M, Coletti AT, Mosca L. Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. Prog Cardiovasc Dis. 1998;41:95-116. (Pubitemid 28480887)
52. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther. 2000;14:681-90. (Pubitemid 32217192)
53. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother. 2002;36:392-7. (Pubitemid 34205308)
54. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet. 2004;43:943-50. (Pubitemid 39447035)
55. Brown KS, Armstrong IC, Wang A, Walker JR, Noveck RJ, Swearingen D, et al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Clin Pharmacol. 2010. doi:10.1177/0091270009349378.
56. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:22Q-25Q. (Pubitemid 28524916)
57. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-74.
58. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-64.
59. Cabrera MA, de Andrade SM, Mesas AE. A prospective study of risk factors for cardiovascular events among the elderly. Clin Interv Aging. 2012. doi:10.2147/CIA.S37211.
60. Mazza A, Tikhonoff V, Schiavon L, Casiglia E. Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly. Intern Med J. 2005. doi:10.1111/j.1445-5994. 2005.00940.x.
61. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord. 2009. doi:10.1089/met.2009.0007.